Track the DIASORIN stock price and the full directors' dealings record of the company, a publicly traded company based in Italy. Shares trade on the IT market, under the authority of Consob. Operating in the Health Care sector, DIASORIN has published 35 insider filings. Market capitalisation: €3.3bn. The latest transaction was disclosed on 10 November 2025 (Other). Among the most active insiders: CHEN MENACHEM EVEN. All data is openly available.
35
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€43m
33 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate DIASORIN Hold (neutral), based on 14 analysts. Average price target: €70.16.
15Σ signal
Buys n/a€43m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,428 of 28,832 companies
61.9
score / 100
Value
58
Quality
66
FCF yld5.5%
Earn yld4.2%
EV/EBITDA12.3x
ROE9.2%
Gross mgn65%
Net mgn13%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
18,465 shares@ €76.240.040% mcap36.0% of flowShareXMILISINISIN IT0003492391CONSOB:153874
25 of 35 declarations
About DIASORIN
DIASORIN is a company focused on in vitro diagnostics, providing solutions for the detection of infectious diseases and chronic conditions. It is listed on the Italian stock market, XMIL.